Fairvalue-Calculator Fairvalue-Calculator
EN DE

MacroGenics, Inc (MGNX) Fair Value & Analysis

Healthcare · US · Market cap $263M

Price$4.69
Fair Value$3.94
Upside-16.0%
Quality95/100
Evidence: Low Range $2.95 – $4.92

Fair value as of: Jun 24, 2026

Analysis

MacroGenics, Inc (MGNX) currently trades at $4.69, while our model-based Fair Value estimate is $3.94 — implying the stock looks roughly 16.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cel…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is MacroGenics, Inc (MGNX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $3.94 versus a price of $4.69 — about −16% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MGNX?
Our 21-model fair value for MacroGenics, Inc is $3.94 (as of Jun 24, 2026), built from audited fundamentals. The current price is $4.69.
What is the quality score of MGNX?
MacroGenics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.